Phase 2 study of the bispecific T-cell engager (bite) antibody Blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Blood

Volumn 127, Issue 11, 2016, Pages 1410-1416

  Viardot, Andreas ^a   Goebeler, Marie Elisabeth ^b   Hess, Georg ^c   Neumann, Svenja ^d   Pfreundschuh, Michael ^e   Adrian, Nicole ^e   Zettl, Florian ^f   Libicher, Martin ^g   Sayehli, Cyrus ^b   Stieglmaier, Julia ^h   Zhang, Alicia ⁱ   Nagorsen, Dirk ⁱ   Bargou, Ralf C ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^g Diakoniekrankenhaus Schwäbisch Hall   (Germany)

^h Amgen Research GmbH   (Germany)

ⁱ AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; C REACTIVE PROTEIN; CD19 ANTIGEN; CD3 ANTIGEN; DEXAMETHASONE; GLUCOSE; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; TUMOR ANTIGEN;

ADULT; AGED; APHASIA; ARTICLE; BACKACHE; BRAIN DISEASE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONFUSION; CONTINUOUS INFUSION; COUGHING; DEVICE INFECTION; DIARRHEA; DISORIENTATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LARGE CELL LYMPHOMA; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA; RELAPSE; RELAPSED DIFFUSE LARGE B CELL LYMPHOMA; RETREATMENT; SINGLE DRUG DOSE; SOMNOLENCE; SPEECH DISORDER; THROMBOCYTOPENIA; TREMOR; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEUROLOGIC DISEASE; RECURRENT DISEASE; REMISSION; SALVAGE THERAPY; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTIGENS, CD3; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FEVER; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NERVOUS SYSTEM DISEASES; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; TUMOR BURDEN;

EID: 84962511553     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-06-651380     Document Type: Article

References (29)

1. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366(21):2008-2016.
2. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117-122.
3. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(12):3776-3785.
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-1545.
5. Lazarus HM, Zhang MJ, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010;16(1):35-45.
6. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190.
7. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941-4944.
8. Mølhøj M, Crommer S, Brischwein K, et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol. 2007;44(8):1935-1943.
9. Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific singlechain antibody construct. Int J Cancer. 2005;115(1):98-104.
10. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226-6233.
11. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974-977.
12. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
13. Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134-4140.
14. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, singlearm, phase 2 study. Lancet Oncol. 2015;16(1):57-66.
15. Goebeler M, Viardot A, Noppeney R, et al. Blinatumomab (CD3/CD19 BITE antibody) results in a high response rate in patients with relapsed non-Hodgkin lymphoma (NHL) including MCL and DLBCL [abstract]. Ann Oncol. 2011;22(Suppl 4). Abstract 068.
16. Viardot A, Goebeler M, Noppeney R, et al. Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma [abstract]. Blood. 2011;118(21). Abstract 1637.
17. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: The International Agency for Research on Cancer; 2008.
18. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10.
19. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
20. Advani R, Chen AI, Lebovic D, et al. Final results of a phase I study of the anti-CD22 antibody-drug conjugate (ADC) DCDT2980S with or without rituximab (rtx) in patients (pts) with relapsed or refractory (R/R) B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood. 2013;122(21). Abstract 4399.
21. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110(1):54-58.
22. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622-1627.
23. Lesokhin AM, Ansell SM, Armand P, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies [abstract]. Blood. 2014;124(21). Abstract 291.
24. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085-2093.
25. Wilson WH, Gerecitano JF, Goy A, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (pci-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract]. Blood. 2012;120(21). Abstract 686.
26. Younes A, Salles G, Bociek RG, et al. An openlabel phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma [abstract]. Blood. 2014;124(21). Abstract 1718.
27. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptortransduced T cells. Blood. 2012;119(12):2709-2720.
28. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549.
29. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.